CCDC86

Across TCGA pan-cancer cohorts, CCDC86 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC86 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CCDC86 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC86 expression acts as an unfavorable survival marker.

ESCA, BLCA, and LUAD are the cancer types where CCDC86 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.198	0.872	.003	18	view →
BLCA	DFS	Median	All	0.212	0.627	.016	18	view →
LUAD	OS	Median	All	0.090	0.788	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC86–ESCA (OS)

Open the ESCA breakdown →